Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
3.450
-0.130 (-3.63%)
Aug 17, 2026, 3:19 PM EDT - Market open

Decoy Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.23----1.84
Revenue Growth
------64.84%
Gross Profit
0.23-----6.71
Operating Income
-6.1-4.1-5.73-12.89-22.98-12.81
Net Income
-14.45-12.52-5.58-12.54-31.61-12.77
Earnings Per Share
-40.40-129.10-69.54---
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8.2910.712.435.912.1129.21
Total Debt
--0.220.29--
Net Cash (Debt)
8.2910.712.215.6112.1129.21
Net Cash Growth
942.81%384.03%-60.56%-53.66%-58.56%174.53%
Net Cash Per Share
23.17110.4527.59---

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-8.32-4.83-4.53-12.85-17.6-10.2
Capital Expenditures
-0.04-----
Free Cash Flow
-8.37-4.83-4.53-12.85-17.6-10.2
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%-----
Operating Margin
-2679.30%-----696.27%
Pretax Margin
-6347.85%-----693.84%
Profit Margin
-6347.85%-----693.84%
FCF Margin
-3675.70%-----554.29%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
8.37----12.17